Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma Clinical Trial

Official title:

A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03073785
• Other study ID #: 0552-16-FB
• Secondary ID: NCI-2016-01360P3
• Status: Recruiting
• Phase: Phase 2
• Start date: September 16, 2016
• Est. completion date: December 2027

Study information

• Verified date: January 2024
• Source: University of Nebraska
• Contact: Chi Lin, MD, PhD
• Phone: 402-552-3879
• Email: clin[@]unmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid work in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating patients with pancreatic cancer.

Description:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of hypofractionated radiation therapy concurrently with zoledronic acid (Zometa) and fluorouracil (5Fu) or capecitabine.

SECONDARY OBJECTIVES:

I. To examine the toxicity of Zometa while it is used concurrently with hypofractionated radiation therapy.

II. To evaluate local failure-free survival and overall survival, surgical resection rate and tumor response rate.

TERTIARY OBJECTIVES:

I. To quantify the amplitude of the expression of genes that are involved in cholesterol biosynthesis (ACAT2, DHCR7, ELFN2, FASN, SC4MOL, and SQLE) in pancreatic tumor tissue prior to and following the Zometa and radiation therapy if the pancreatic cancer tissue is available.

II. To measure Zometa pharmacokinetics at steady-state. III. To evaluate tumor and organ motion with 4 dimension(D) computed tomography (CT) and respiratory gating system and to evaluate the effect of tumor/organ motion on the dosimetry, local control and survival.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil intravenously (IV) over 24 hours on day 1 weekly for 4 weeks or capecitabine orally (PO) every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.

ARM B: Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.

After completion of study treatment, patients are followed up for 30 days, every 3 months for the first year, every 4 months for the second year, and then every 6 months thereafter.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: December 2027
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Pathologically confirmed adenocarcinoma of the pancreas; patients with either initially diagnosed or recurrent locally advanced disease; the maximum dimension of the treatment target must be =<10 cm; locally advanced disease defined as: T 1-2N+MO or T3-4 NxMo, or borderline resectable and unresectable adenocarcinoma without distant metastatic disease or resectable T3-4 NxMo disease or M1 with controlled distant disease

• Patients with inoperable conditions with resectable disease (T1-2NoMo)

• Karnofsky performance status of 60% or better

• Patients who received recent chemotherapy for pancreatic cancer are eligible; patients who received chemotherapy > 5 years ago for malignancies other than pancreatic cancer are also eligible, provided that chemotherapy was completed > 5 years ago and that there is no evidence of the second malignancy at the time of study entry

• Patients who received radiation therapy > 5 years ago for malignancies other than pancreatic cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field are eligible, provided that radiation therapy was completed > 5 years ago and that there is no evidence of the second malignancy at the time of study entry

• All malignant disease must be able to be encompassed within a single irradiation field

• Patients must have an absolute neutrophil count (ANC) greater than or equal to 1500/uL

• All patients must have radiographically assessable disease

• Platelet count greater than or equal to 100,000/uL

• Patients must have a serum creatinine less than or equal to 2.0 mg/dL and total bilirubin less than or equal to 2.0 mg/dL in the absence of biliary obstruction; if the patient has biliary obstruction, biliary decompression will be required; either endoscopic placement of a biliary stent or percutaneous transhepatic drainage is acceptable; once biliary drainage has been established, institution of protocol therapy may proceed when the total bilirubin falls to 4.0 mg/dL or lower)

• Patients must have a calculated creatinine clearance of >= 35

• The patient must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts

Exclusion Criteria:

• Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy

• Uncontrolled inter-current illness including, but not limited to ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia, that might jeopardize the ability of the patient to receive the therapy program outlined in this protocol with reasonable safety

• Pregnant and nursing women are excluded from this study

• Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years

• Patients with active duodenal ulcer or bleeding or history of a gastrointestinal fistula or perforation or other significant bowel problems (severe nausea, vomiting, inflammatory bowel disease and significant bowel resection)

• Patients with known human immunodeficiency virus (HIV) infection, or hepatic insufficiency

• Patients may not be receiving or have received Zometa during/or within 3 weeks prior to treatment with Zometa

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Neoplasms
• Recurrent Pancreatic Carcinoma
• Stage I Pancreatic Cancer AJCC v6 and v7
• Stage IA Pancreatic Cancer AJCC v6 and v7
• Stage IB Pancreatic Cancer AJCC v6 and v7
• Stage II Pancreatic Cancer AJCC v6 and v7
• Stage IIA Pancreatic Cancer AJCC v6 and v7
• Stage IIB Pancreatic Cancer AJCC v6 and v7
• Stage III Pancreatic Cancer AJCC v6 and v7
• Stage IV Pancreatic Cancer AJCC v6 and v7

Intervention

Drug:
• Capecitabine
Given PO
• Fluorouracil
Given IV

Other:
• Laboratory Biomarker Analysis
Correlative studies
• Pharmacological Study
Correlative studies

Radiation:
• Stereotactic Body Radiation Therapy
Undergo hypofractionated stereotactic radiotherapy

Drug:
• Zoledronic Acid
Given IV

Locations

Country	Name	City	State
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
University of Nebraska	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	RNA seq will be used to assess gene expression involved in cholesterol biosynthesis in patients who had resection with or without Zometa	Change in expression of genes involved in cholesterol biosynthesis in patients who undergo resection will be assessed.	up to 5 years
Other	Pharmacokinetics parameters of zoledronic acid	The concentration of plasma zoledronic acid will be measured.in patients who received zoledronic acid	At 0 and 1 hours post zoledronic acid dose, and before radiation treatments on days 2, 3, 4, and 5
Primary	Local control	Will be observed.	At 4 months
Primary	Local control	Will be observed.	At 8 months
Primary	Local control	Will be observed.	At 12 months
Secondary	Maximum tolerated dose of zoledronic acid determined by dose limiting toxicities evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	Safety variables to be analyzed are adverse events. Adverse events will be tallied for overall frequency (number and percentage of subjects), worst reported severity, and relationship to study drugs. Serious adverse events will be summarized similarly.	Up to 30 days after surgery
Secondary	Local failure-free survival will be compared between patients with and without Zometa	Time to local failure will be analyzed using Kaplan-Meier method	From date of administration of study drug to the date of first appearance of local disease progression or recurrence by imaging, or death, assessed up to 5 years
Secondary	Overall survival will be compared between patients with and without Zometa	Time to death will be analyzed using Kaplan-Meier method	From the first date of study drug to the date of death, assessed up to 5 years
Secondary	Surgical complete resection (negative margin) rate will be compared between patients with and without Zometa	The number and proportion of patients undergoing complete resection will be reported.	Immediate after the surgery
Secondary	Pathologic response for patients who undergo resection will be compared between patients with and without Zometa	The pathologic response will be scored from 0-9 by a pathologist, 0 is no response and 9 is complete response.	Immediate after surgery
Secondary	The change of tumor size after SBRT will be compared between patients with and without Zometa	The size of tumor will be measured on CT/MRI before and after SBRT	within 1 months prior to SBRT and 4-5 weeks after SBRT
Secondary	The change of max and average SUV after SBRT will be compared between patients with and without Zometa.	The max and average SUV will be measured on PET before and after SBRT	within 1 months prior to SBRT and 4-5 weeks after SBRT
Secondary	Tumor and organ motion	The amplitude of 3D tumor/organ motion will be measured using 4D CT scans	Immediate prior to SBRT